Literature DB >> 28425076

Monoclonal gammopathy of renal significance (MGRS): the characteristics and significance of a new meta-entity.

Mariana Ciocchini1, Jorge Arbelbide2, Carlos G Musso3.   

Abstract

Monoclonal gammopathy of renal significance (MGRS) is a new nosological group of entities (meta-entity) defined in 2012, whose pathogenesis depends on monoclonal immunoglobulins (Ig) secreted by low-grade lymphoproliferative disorders, which belong to M-protein-related diseases. Renal damage is the result of monoclonal Ig deposit or its activity as autoantibodies, which can compromise any nephronal area. MGRS does not include kidney diseases produced by high-grade lymphoproliferative disorders as well as those whose pathogenesis are independent of monoclonal Ig (such as drug toxicity or metabolic disorders). The importance of this hemato-nephrological meta-entity is based on two aspects: First, it is associated with increased morbidity and mortality, including recurrence in post-renal transplant or its appearance as "de novo" after it; and second, it usually improves after treating the plasmocyte or lymphocyte clone responsible, leading to the elimination of M-protein. Between low-grade lymphoproliferative disorders, monoclonal gammopathy of undetermined significance (MGUS) requires special consideration for two reasons: First, it is the disorder most related to MGRS; second, when MGUS progresses to MGRS, effective treatment against toxic underline clone should be performed taking into account the nephrological perspective.

Entities:  

Keywords:  Kidney disease; Monoclonal gammopathy of undetermined significance (MGUS); Paraproteinemias

Mesh:

Substances:

Year:  2017        PMID: 28425076     DOI: 10.1007/s11255-017-1594-y

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  37 in total

1.  Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis.

Authors:  Sanjeev Sethi; Jason D Theis; Nelson Leung; Angela Dispenzieri; Samih H Nasr; Mary E Fidler; Lynn D Cornell; Jeffrey D Gamez; Julie A Vrana; Ahmet Dogan
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

2.  Outcomes of Monoclonal Gammopathy of Undetermined Significance in Patients Who Underwent Kidney Transplantation.

Authors:  I Bancu; L Cañas; F J Juega; M Pérez; S Malumbres; J Bonet; R Lauzurica
Journal:  Transplant Proc       Date:  2015-10       Impact factor: 1.066

3.  Early recurrence of proliferative glomerulonephritis with monoclonal immunoglobulin deposits in a renal allograft.

Authors:  Rohit Tewari; Kusum Joshi; Ashwani Kumar; C S Rayat; Rajaram Iyer; Vinay Sakhuja; Mukut Minz
Journal:  Saudi J Kidney Dis Transpl       Date:  2016-03

Review 4.  Multiple myeloma: Diagnosis and management issues in patients with pre-existing chronic kidney disease.

Authors:  Srilatha Vadlamudi; Siva Nagendra Reddy Annapareddy
Journal:  Saudi J Kidney Dis Transpl       Date:  2016-01

5.  Dense deposit disease associated with monoclonal gammopathy of undetermined significance.

Authors:  Sanjeev Sethi; William R Sukov; Yuzhou Zhang; Fernando C Fervenza; Donna J Lager; Dylan V Miller; Lynn D Cornell; Srivilliputtur G Santhana Krishnan; Richard J H Smith
Journal:  Am J Kidney Dis       Date:  2010-09-15       Impact factor: 8.860

Review 6.  The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease.

Authors:  Punit Yadav; Nelson Leung; Paul W Sanders; Paul Cockwell
Journal:  Kidney Int       Date:  2014-10-08       Impact factor: 10.612

Review 7.  How I treat monoclonal gammopathy of renal significance (MGRS).

Authors:  Jean-Paul Fermand; Frank Bridoux; Robert A Kyle; Efstathios Kastritis; Brendan M Weiss; Mark A Cook; Mark T Drayson; Angela Dispenzieri; Nelson Leung
Journal:  Blood       Date:  2013-10-09       Impact factor: 22.113

8.  Recurrent membranous nephropathy in an allograft caused by IgG3κ targeting the PLA2 receptor.

Authors:  Hanna Debiec; Melanie Hanoy; Arnaud Francois; Dominique Guerrot; Sophie Ferlicot; Catherine Johanet; Pierre Aucouturier; Michel Godin; Pierre Ronco
Journal:  J Am Soc Nephrol       Date:  2012-11-02       Impact factor: 10.121

9.  Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.

Authors:  Colin A Hutchison; Tim Plant; Mark Drayson; Paul Cockwell; Melpomeni Kountouri; Kolitha Basnayake; Stephen Harding; Arthur R Bradwell; Graham Mead
Journal:  BMC Nephrol       Date:  2008-09-22       Impact factor: 2.388

10.  A case of podocytic infolding glomerulopathy with multiple myeloma.

Authors:  Makoto Harada; Yuji Kamijo; Takashi Ehara; Hisashi Shimojo; Hidekazu Shigematsu; Makoto Higuchi
Journal:  BMC Nephrol       Date:  2014-02-13       Impact factor: 2.388

View more
  10 in total

Review 1.  Pathophysiology and management of monoclonal gammopathy of renal significance.

Authors:  Ankur Jain; Richard Haynes; Jaimal Kothari; Akhil Khera; Maria Soares; Karthik Ramasamy
Journal:  Blood Adv       Date:  2019-08-13

2.  Which should be the correct treatment for monoclonal gammopathy of renal significance with complement alternative pathway dysregulation (C3 glomerulopathy and atypical hemolytic uremic syndrome): clone-directed or anticomplement therapy?

Authors:  Mariana Ciocchini; Carlos G Musso
Journal:  Int Urol Nephrol       Date:  2018-05-28       Impact factor: 2.370

3.  Monoclonal Gammopathies and Kidney Disease: Searching for Significance.

Authors:  Christina Hao Wang; Jonathan J Hogan
Journal:  Clin J Am Soc Nephrol       Date:  2018-11-15       Impact factor: 8.237

4.  What is the place of POEMS syndrome in the current classification of monoclonal gammopathies of renal significance?

Authors:  Mariana Ciocchini; Carlos Guido Musso
Journal:  Int Urol Nephrol       Date:  2017-11-13       Impact factor: 2.370

5.  Kidney Histopathologic Spectrum and Clinical Indicators Associated with MGRS.

Authors:  Zi-Hao Yong; Xiao-Juan Yu; Jing-Xia Liu; Fu-de Zhou; Su-Xia Wang; Ming-Hui Zhao
Journal:  Clin J Am Soc Nephrol       Date:  2022-02-24       Impact factor: 8.237

6.  Monoclonal gammopathy of undetermined significance coexisting in patients undergoing kidney transplantation does not adversely influence post-graft clinical outcome.

Authors:  Roberta Clari; Corrado Tarella; Roberta Giraudi; Maria Cristina Torazza; Ester Gallo; Antonio Lavacca; Fabrizio Fop; Alberto Mella; Caterina Dolla; Luigi Biancone
Journal:  Clin Kidney J       Date:  2020-09-18

7.  A case of monoclonal gammopathy of undetermined significance and minimal change disease complicated by bilateral pulmonary emboli.

Authors:  Thanuja Neerukonda; Alexandra Witt; Arsen Tan; Bilal Farooqi; Yasna Chaudhary; Christina Kovacs; Luis Silva
Journal:  SAGE Open Med Case Rep       Date:  2022-08-12

8.  Clinicopathological characteristics of patients with paraproteinemia and renal damage.

Authors:  Xuanli Tang; Feng Wan; Jin Yu; Xiaohong Li; Ruchun Yang; Bin Zhu
Journal:  Eur J Med Res       Date:  2021-07-03       Impact factor: 2.175

9.  Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients.

Authors:  Normann Steiner; Georg Göbel; Hannes Neuwirt; Eberhard Gunsilius; Patricia Suchecki; Wolfgang Prokop
Journal:  Oncotarget       Date:  2017-12-18

10.  Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort.

Authors:  Maxine Je Lamb; Alexandra Smith; Daniel Painter; Eleanor Kane; Timothy Bagguley; Robert Newton; Debra Howell; Gordon Cook; Ruth de Tute; Andrew Rawstron; Russell Patmore; Eve Roman
Journal:  BMJ Open       Date:  2021-02-22       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.